Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: Cost-effectiveness in refractory epilepsy

Clinical Drug Investigation

Volumn 23, Issue 4, 2003, Pages 225-232

  Maltoni, S ^a   Messori, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; EPILEPSY; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 0037262718     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323040-00002     Document Type: Article

References (30)

1. Cockerell OC, Hart YM, Sander JWAS, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994; 18: 249-60
2. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-43
3. Cockerell OC, Sander JWAS, Shorvon SD. Neuroepidemiology in the UK. J Neurol Neurosurg Psychiatry 1993; 56: 735-8
4. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-37
5. Smith D, Baker GA, Chadwick DW, et al. The contribution of the measurement of seizure severity to quality of life research. Qual Life Res 1995; 4: 143-58
6. Vickery BG, Hays RD, Engel J, et al. Outcome assessment for epilepsy surgery: the impact of measuring health-related quality of life. Ann Neurol 1995; 37: 158-66
7. Klenerman P, Sander JWAS, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long-term residential care. J Neurol Neurosurg Psychiatry 1993; 56: 149-52
8. Hauser WA, Annegers JF, Elveback LR. Mortality in patients with epilepsy. Epilepsia 1980; 21: 399-412
9. O'Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995; 4: 37-44
10. Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia 2002; 43: 550-8
11. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8
12. Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53: 421-7
13. Mark DB. Economic analysis methods and end-points. In: Califf RM, Mark DB, Wagner B, editors. Acute coronary care in the thrombolytic era. St Louis: Mosby, 1995: 167-182
14. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
15. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332: 719-24
16. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of alpha-interferon alpha in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 2673-82
17. Messori A, Becagli P, Trippoli S. Cost-effectiveness of interferon as maintenance treatment in chronic myeloid leukemia [letter]. Ann Intern Med 1997; 126: 664-5
18. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6
19. Messori A, Becagli P, Trippoli S, et al. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. [published erratum appears in Eur J Clin Pharmacol 1996; 51: 427]. Eur J Clin Pharmaco] 1996; 51: 111-6
20. Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of adjuvant intmportal chemotherapy in patients with colorectal cancer. J Clin Gastronterol 1996; 23: 269-74
21. Messori A, Trippoli S, Becagli P, et al. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366-73
22. Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 275-81
23. Messori A, Cecchi M, Becagli P, et al. Cost-utility analysis based on a lifetime approach: application of a modified Q-TWIST method and reappraisal of paclitaxel as first-line chemotherapy for advanced ovarian cancer [letter]. Cancer 1997; 79: 2264-6
24. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics 2002; 20 Suppl. 3: 95-105
25. Hutchison TA, Shahan DR, editors. DRUGDEX® System. MICROMEDEX, Greenwood Village (CO), Healthcare Series Vol. 114, 2002
26. Guberman A, Neto W, Gassmann-Mayer C. Low dose topiramate in adults with treatment resistant partial onset seizures. Acta Neurol Scand 2002; 106 (4): 183-9
27. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998; 39: 776-86
28. Netten A, Dennet J. Unit costs of health and social care. University of Kent: Personal Social Services Research Unit, 2001
29. Monthly index of medical specialities (2001 Oct). London, Haymarket Publishing Services Ltd, 2001
30. Heaney DC, Sander JWAS, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res 2001; 43: 89-95